FAQ on Aditxt Inc.'s Termination of Acquisition Agreement with Appili Therapeutics

What is the main reason Aditxt Inc. terminated its agreement with Appili Therapeutics?

Aditxt Inc. cited a lack of strategic alignment as the primary reason for terminating the acquisition agreement with Appili Therapeutics Inc., despite ongoing respect for Appili’s work.

When will the termination of the agreement take effect?

The termination of the agreement is set to take effect on May 31, 2025.

Where can I find the full press release about this termination?

The full press release can be viewed at https://ibn.fm/KSrpJ.

What is Aditxt Inc.’s mission?

Aditxt Inc. is dedicated to accelerating promising health innovations through its ecosystem of research institutions, industry partners, and shareholders, aiming to ‘Make Promising Innovations Possible Together.’

What programs does Aditxt Inc. currently operate?

Aditxt Inc. currently operates two programs focused on immune health and precision health, with plans to introduce additional programs dedicated to public health and women’s health.

Who is involved in the transactions mentioned besides Appili Therapeutics?

Besides Appili Therapeutics, Aditxt Inc. has entered into a merger agreement with Evofem, focusing on advancing innovative health solutions.

What are the conditions for closing the transactions with Appili and Evofem?

The closing of the transactions is subject to several conditions, including approval by the respective target shareholders and Aditxt raising sufficient capital to fund its obligations at closing.

Where can investors find the latest news and updates relating to ADTX?

The latest news and updates relating to ADTX are available in the company’s newsroom at https://ibn.fm/ADTX.

What is BioMedWire?

BioMedWire is a specialized communications platform focusing on the latest developments in the Biotechnology, Biomedical Sciences, and Life Sciences sectors, part of the Dynamic Brand Portfolio @ IBN.